Tetralysal (lymecycline)
/ Galderma
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
64
Go to page
1
2
3
December 12, 2025
P049 Improving care for patients with acne vulgaris: an audit of oral lymecycline therapy against the NICE guidelines (NG198).
(PubMed, Br J Dermatol)
- "One-half (54%) of patients received a topical treatment, with benzoyl peroxide and adapalene (Epiduo®) being the most common combination. In conclusions, this audit highlights critical gaps in prescribing practices, underscoring the need for systemic improvements to align with NICE guidelines. Interventions such as clinician education, the integration of NICE guidance into clinical systems, and structured treatment reviews are recommended to address these issues."
Journal • Retrospective data • Acne Vulgaris • Dermatology
December 12, 2025
PA28 Cutaneous sarcoidosis mimicking molluscum contagiosum.
(PubMed, Br J Dermatol)
- "In July 2023, dupilumab was commenced by the respiratory team for her severe asthma and it had a beneficial effect on her eczema...Lymecycline 408 mg once daily for 2 months and mometasone furoate 0.1% ointment were commenced but the disease continued to progress. We then commenced doxycycline 100 mg daily alongside mometasone furoate 0.1% ointment due to the patient's strong desire to avoid blood tests...Although it is an uncommon presentation, it is important to be aware of it as a differential diagnosis in cases of atypical molluscum contagiosum. This case, in addition to its severity and rarity, has proven challenging to manage given the patient's severe venepuncture phobia."
Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Ophthalmology • Pediatrics • Pulmonary Disease • Respiratory Diseases • Sarcoidosis
December 12, 2025
BH28 Breaking the pattern: frontal fibrosing alopecia in men, a case series.
(PubMed, Br J Dermatol)
- "Treatment with topical corticosteroids, lymecycline, doxycycline and hydroxychloroquine led to partial stabilization, although significant psychological distress persisted. In 2023 a genome-wide association study also identified two genes associated with male FFA, which were different from genes implicated in women. These cases highlight the potential for further research into possible environmental and genetic triggers and novel treatment approaches."
Journal • Alopecia • CNS Disorders • Dermatology • Dermatopathology • Fibrosis • Immunology • Infectious Disease • Inflammation • Lichen Planus • Novel Coronavirus Disease
November 08, 2025
Unilateral palpebral lupus miliaris disseminatus faciei successfully treated with lymecycline.
(PubMed, An Bras Dermatol)
- No abstract available
Journal • Immunology • Inflammatory Arthritis • Lupus
July 23, 2025
Successful Treatment of Pyoderma Vegetans with Lymecycline: First Case Report
(EADV 2025)
- "Two cases reported in the literature showed a good response to doxycycline. This case report highlights the potential of lymecycline in the treatment of pyoderma vegetans, constituting, to our knowledge, the first documented case of successful treatment with this antibiotic. Further studies are needed to validate these results."
Case report • Clinical • Asthma • Dermatology • Diabetes • Immunology • Metabolic Disorders • Respiratory Diseases • Type 2 Diabetes Mellitus
July 23, 2025
Shedding Light on Effective Management of Acne Keloidalis Nuchae: The Utility of Excimer Pulsed Light Therapy
(EADV 2025)
- "Previous treatments included three intralesional triamcinolone injections at two-month intervals (10–40 mg/mL), a four-month course of topical fluocinolone acetonide gel, and oral lymecycline (408 mg daily), all of which had minimal impact. To our knowledge, this is the first reported use of EPL for AKN. While other UV wavelengths have demonstrated efficacy in previous studies, evidence supporting the use of UVB for this condition remains limited. This case highlights EPL as a safe and effective treatment for AKN."
Acne Vulgaris • Alopecia • Atopic Dermatitis • Fibrosis • Genetic Disorders • Pruritus • Psoriasis • Skin Cancer • Thermal Injury
July 23, 2025
Posterior Reversible Encephalopathy Syndrome as a Potential Complication of Adalimumab in a Patient with Hidradenitis Suppurativa
(EADV 2025)
- "Her HS was refractory to multiple treatments, including oral antibiotics (lymecycline, erythromycin, clindamycin/rifampicin—poorly tolerated) and topical agents...The patient remains seizure-free on Levetiracetam, though her HS has begun to flare since stopping Adalimumab...Early recognition and drug withdrawal are key to preventing long-term morbidity. Further research is needed to clarify the association between anti-TNF agents and PRES across specialties."
Clinical • Cardiovascular • CNS Disorders • Crohn's disease • Dermatology • Epilepsy • Gastroenterology • Hidradenitis Suppurativa • Hypertension • Immunology • Infectious Disease • Inflammatory Bowel Disease • Melanoma • Solid Tumor
July 23, 2025
The role of a multidisciplinary approach in the management of Hidradenitis Suppurativa in a patient with multiple co-morbidities: A case report
(EADV 2025)
- "Her HS, diagnosed in 2021, had been managed conservatively with long-term lymecycline and antiseptic washes... This case exemplifies the intricate interplay between HS and systemic disease, highlighting how comorbidities can obscure clinical presentation and complicate management. Importantly, it underscores the value of early and proactive multidisciplinary collaboration in addressing the physical, metabolic, infectious, gastrointestinal, and psychological dimensions of HS. Dermatologists are uniquely positioned to lead these collaborative care pathways."
Case report • Clinical • Candidiasis • Cardiovascular • Crohn's disease • Dermatology • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hidradenitis Suppurativa • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus • Urology
July 23, 2025
Tertiary Centre Experience with Secukinumab in Hidradenitis Suppurativa: A Patient Survey
(EADV 2025)
- "Antibiotic use remained high, with 45% reporting five or more courses in the past year and doxycycline, lymecycline, and co-amoxiclav were the antibiotics more commonly prescribed. Secukinumab was generally well tolerated, but symptom improvement was inconsistent. Many participants continued to experience frequent, severe flare-ups and relied heavily on antibiotics, indicating incomplete disease control. Qualitative responses emphasized the need for better communication, personalized care, and consideration of alternative or adjunctive treatments."
Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • IL17A
July 23, 2025
Antibiotic Use in Patients with Hidradenitis Suppurativa Treated with Adalimumab vs Secukinumab: A Real-World Patient Survey
(EADV 2025)
- "Antibiotic types varied: Adalimumab users most commonly cited doxycycline, rifampicin, and co- amoxiclav, while secukinumab users listed doxycycline, amoxicillin, clarithromycin, and lymecycline. Antibiotic use remains high among patients with HS treated with biologics, especially in those receiving secukinumab. This group appeared to need more frequent antibiotic courses despite limited perceived benefit, which may reflect greater disease severity, as Secukinumab is currently used as a second-line therapy. A key limitation is that secukinumab users had generally been on treatment for a shorter time, possibly influencing these trends."
Clinical • Real-world • Real-world evidence • Dermatology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology
August 11, 2025
Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications.
(PubMed, Nanomedicine (Lond))
- "Lymecycline-loaded α-Fe₂O₃ NPs exhibited pH-responsive drug release, selective cytotoxicity toward THP-1 cancer cells, strong antibacterial efficacy, and good biocompatibility with normal cells. These findings highlight their dual functionality and potential as a promising nanoplatform for future anticancer and antimicrobial therapies."
Journal • Infectious Disease • Oncology
June 02, 2025
Molecularly Imprinted Nanoparticle-Based Assay for Tetracycline Determination at Subnanomolar Levels.
(PubMed, ACS Omega)
- "MINs with hydrodynamic radii ranging from 200 to 300 nm were synthesized via solid-phase imprinting on magnetic nanoparticles using lymecycline (LMC) as an auxiliary template. Within the studied concentration range, the analytical responses of MINs were two to five times higher than those obtained from nonimprinted materials or blank controls. These findings support the performance of MINs as antibody mimetics with high recognition capacity, relatively low production costs, and robust analytical applications."
Journal
November 29, 2024
Pemphigoid lichen planus effectively treated with lymecycline
(JDP 2024)
- No abstract available
Dermatology • Dermatopathology • Immunology • Lichen Planus
November 17, 2024
First Trimester Tetracycline Exposure and Risk of Major Congenital Malformations.
(PubMed, JAMA Netw Open)
- "The RRs for specific tetracycline substances were 1.07 (95% CI, 0.93-1.23) for doxycycline, 0.83 (95% CI, 0.60-1.15) for lymecycline, and 0.78 (95% CI, 0.32-1.92) for tetracycline-oxytetracycline. In this cohort study, first trimester tetracycline exposure was not associated with increased risks of any MCMs. Additional studies are needed to rule out potential risks owing to power limitations for several MCM subgroups and individual malformations."
Journal
October 30, 2024
In silico drug repurposing using molecular docking and dynamics to target the protein interaction between the SARS-CoV-2 S-glycoprotein and the ACE2 receptor.
(PubMed, F1000Res)
- " Our study is unique in its comprehensive approach to identify agents that can bind to the S-glycoprotein-ACE2 interface using multiple computational platforms. Among the hit compounds shortlisted in this study, both lymecycline and hexoprenaline may be considered as candidates for preliminarily clinical studies to assess their therapeutic potential in the management of COVID-19 infections."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
August 06, 2024
efficacy and tolerability of the combination adapalene and benzoyl peroxide 0.1%/2.5%, gel in the management of acne vulgaris
(EADV 2024)
- "These patients were treated with a combination of oral Tetralysal 300 mg and topical adapalene 0.1%/benzoyl peroxide 2.5% (Gr A) .The second group consisted of 62 patients with mild to moderate acne... Combination therapy is commonly used to treat acne because of its proven efficacy in treating this complex, chronic condition. The fixed-dose combination of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% offers a therapeutic approach combining two agents that act in different ways to target the multiple pathophysiological factors responsible for acne . Our results suggest that this combination is globally effective and well tolerated, both as monotherapy and in combination with oral therapy."
Clinical • Acne Vulgaris • Dermatology • Infectious Disease • Inflammation
June 06, 2024
Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia
(BAD 2024)
- "Initial management was lymecycline 408 mg once daily, tacrolimus 0.1% ointment twice daily plus mometasone furoate 0.1% two times weekly to the neck, and pimecrolimus cream twice a day to the face, as well as a sun protection factor 50 sunscreen...Lymecycline was stopped and hydroxychloroquine 200 mg once daily was started...Low-dose isotretinoin has been reported as being of benefit in LP pigmentosus but was ineffective in this case. Mycophenolate mofetil is also reported to be of benefit in the management of LP pigmentosus, and led to a significant improvement in both pigmentation and itch in this case. This case highlights the therapeutic benefit of mycophenolate mofetil in in LP pigmentosus associated with FFA."
Clinical • Alopecia • Dermatology • Dermatopathology • Fibrosis • Immunology • Lichen Planus • Pruritus
June 06, 2024
In over our heads?
(BAD 2024)
- "He was on lymecycline at the time of presentation, prescribed by his general practitioner, and no other medications...He was treated with rifampicin and clindamycin, in multiple short courses and once consecutively for 6 months, which yielded some improvement...He was treated with flucloxacillin (500 mg, four times daily for 2 weeks), followed by doxycycline (100 mg daily for 6 weeks), followed by azithromycin (500 mg, three times weekly for 4 weeks). He has achieved considerable improvement and is being considered for oral dapsone...This case depicts the severe end of the disease spectrum, and the issues that can arise in that context. Challenges faced by his team were not only medical, but also psychological by way of gaining the patient's trust and managing vulnerabilities."
Acne Vulgaris • Alopecia • Dermatology • Immunology • Infectious Disease • Inflammation • Pruritus
June 08, 2024
Computational drug repurposing screen targeting PLA2R antibody binding.
(UKKW 2024)
- "The sixteen compounds include Lymecycline, Trazodone, Mirabegron, Sulfasalazine, Methotrexate, Rosuvastatin and Montelukast. However, they all share the chemical properties of large molecular weight and have the potential to form multiple hydrogen bonds. If validated experimentally, these compounds could provide new treatment options for PLA2R antibody positive membranous nephropathy."
Glomerulonephritis • Renal Disease
March 22, 2024
The effect of lymecycline on paediatric cystic fibrosis related diabetes in the modulator era
(ECFS 2024)
- "This case shows that lymecycline treatment used for acne, can trigger glucose intolerance, but after discontinuation this restores to baseline levels. If lymcycline is commenced, we propose closer monitoring of blood glucose, and alternative treatment if problems of CFRD arise."
Acne Vulgaris • Cystic Fibrosis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Pediatrics • Pulmonary Disease • Respiratory Diseases
March 23, 2024
Computational drug repurposing screen targeting PLA2R antibody binding.
(ERA-EDTA 2024)
- "The sixteen compounds include Lymecycline, Trazodone, Mirabegron, Sulfasalazine, Methotrexate, Rosuvastatin and Montelukast. Structural bioinformatics methods provide a relatively fast and economical option for identifying protein-drug interactions that could result in new treatment strategies. The compounds identified for investigation are used for an array of different health conditions. However, they all share the chemical properties of large molecular weight and have the potential to form multiple hydrogen bonds."
Glomerulonephritis • Nephrology • Renal Disease
May 11, 2024
Stevens-Johnson syndrome induced by lymecycline in a 17 years old adolescent: A case report and review of the literature
(PubMed, Therapie)
- No abstract available
Journal • Review • Steven-Johnson Syndrome
May 02, 2024
Pediatric Hidradenitis Suppurativa in a Patient with Down Syndrome A Case Report and Review of Literature
(INDERCOS 2024)
- "She was diagnosed with nodular acne and was treated with oral lymecycline, metronidazole and topical mupirocin, clindamycin and chlorhexidine, she did not benefit from them...Adalimumab treatment was started but she discontinued follow-up visits...The US and Canadian HS Foundations have recommended annual HS screening in patients with DS. Given these findings, dermatologists should be aware of association between HS and DS."
Case report • Clinical • Review • Acne Vulgaris • Celiac Disease • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Pain • Pediatrics • APP
February 17, 2024
Is there a Rationale for the Use of Lymecycline for Frontal Fibrosing Alopecia?
(PubMed, Dermatol Pract Concept)
- No abstract available
Journal • Alopecia • Fibrosis • Immunology
January 29, 2024
Hurley Stage 3 Hidradenitis Suppurativa in pregnancy: An area of unmet need(#251)
(EHSF 2024)
- "Treatments prior to pregnancy included tetralysal, metformin rifampicin, clindamycin, adalimumab, ustekinumab, ixekizumab and infliximab, none of which had adequately controlled disease. At the time of conception, HS was stable on certolizumab...Many treatment options utilised in the general population are contraindicated in pregnancy, including oral contraceptives, spironolactone and tetracycline antibiotics...The authors suggest a 12-week course of dapsone, may be attempted with caution as late-line therapy for HS...HS is associated with higher risk pregnancies. Further research in this area of unmet need is warranted."
Anesthesia • Cardiovascular • Dermatology • Gastroenterology • Gynecology • Hidradenitis Suppurativa • Hypertension • Immunology • Infectious Disease • Inflammation • Obstetrics • Rheumatology • Septic Shock
1 to 25
Of
64
Go to page
1
2
3